Iovance registers Phase 2 lifileucel trial in advanced soft tissue sarcoma, 'SARATOGA'
Iovance Biotherapeutics is recruiting for a Phase 2 study testing lifileucel in previously treated advanced soft tissue sarcoma patients.
Iovance Biotherapeutics' trial activity for the week centers on a single newly posted study in soft tissue sarcoma.
- A Phase 2 study of lifileucel, a tumor-infiltrating lymphocyte therapy also known as LN-145, is recruiting for adults with previously treated advanced soft tissue sarcoma, under the sponsor ID IOV-SAR-201 and acronym "SARATOGA" (NCT07741877). The trial has an estimated enrollment of 80 participants1 and focuses on two cohorts, unresectable or metastatic undifferentiated pleomorphic sarcoma (Cohort 1) or dedifferentiated liposarcoma (Cohort 2), in patients who have received at least 1 and up to 3 prior systemic therapies including at least one anthracycline-based regimen1. The primary endpoint is objective response rate measured over a 5-year time frame, evaluated per RECIST v1.1 by independent review1, and the study's actual start date is listed as October 2, 2026, with estimated primary completion in September 2033.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.